Item 7.01 Regulation FD Disclosure.

On January 28, 2021, Lipocine Inc. (the "Company") closed its previously announced underwritten offering of 16,428,571 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 2,142,857 shares of common stock. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






Exhibit No.                  Description
  99.1          Press Release dated January 28, 2021.

© Edgar Online, source Glimpses